Regeneron Pharmaceuticals (REGN Quick QuoteREGN ) has posted a stellar performance so far in the year riding high on the strong demand for REGEN-COV (casirivimab and imdevimab), its antibody cocktail for COVID-19. The demand for the cocktail continues to increase as the pandemic keeps wreaking havoc with emerging deadly variants that question the efficacy of the vaccines.
Demand for antibody treatments is expected to remain strong in the near term as even vaccinated people are now being infected, sometimes even with severe COVID-19.
Regeneron fulfilled its second agreement....More>>>